Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Spinal Cord Diseases

ClinicalTrials.gov lists 3,982 trials for Spinal Cord Diseases or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 78.

MeSH D013118 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 317 Phase 1/2 Phase 1/2 185 Phase 2 Phase 2 434 Phase 2/3 Phase 2/3 95 Phase 3 Phase 3 262 Phase 4 Phase 4 140 Not applicable Not applicable 1,638 Observational Observational 891 Phase 1 Phase 1 317 Phase 1/2 Phase 1/2 185 Phase 2 Phase 2 434 Phase 2/3 Phase 2/3 95 Phase 3 Phase 3 262 Phase 4 Phase 4 140 Not applicable Not applicable 1,638 Observational Observational 891

Trials per phase

1 more section with rows

119 of the 3,982 trials are tagged with Spinal Cord Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Spinal Cord Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Spinal Cord Diseases trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 274

1991: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1992: 3 trials (Observational 2, Phase 2 1) 1993: 2 trials (Observational 1, Not applicable 1) 1994: 1 trials (Observational 1) 1995: 2 trials (Phase 3 1, Phase 2 1) 1996: 8 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 1 1) 1998: 13 trials (Observational 6, Phase 2 6, Phase 1 1) 1999: 9 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1 1) 2000: 10 trials (Observational 1, Not applicable 3, Phase 3 3, Phase 2/3 1, Phase 2 2) 2001: 17 trials (Observational 6, Not applicable 4, Phase 4 3, Phase 3 2, Phase 2 1, Phase 1 1) 2002: 27 trials (Observational 6, Not applicable 5, Phase 4 2, Phase 3 4, Phase 2/3 2, Phase 2 5, Phase 1 3) 2003: 41 trials (Observational 7, Not applicable 7, Phase 4 3, Phase 3 9, Phase 2/3 5, Phase 2 6, Phase 1/2 1, Phase 1 3) 2004: 35 trials (Observational 10, Not applicable 8, Phase 4 2, Phase 3 3, Phase 2 4, Phase 1/2 3, Phase 1 5) 2005: 56 trials (Observational 13, Not applicable 10, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 12, Phase 1/2 7, Phase 1 3) 2006: 74 trials (Observational 15, Not applicable 12, Phase 4 3, Phase 3 22, Phase 2/3 2, Phase 2 14, Phase 1/2 2, Phase 1 4) 2007: 75 trials (Observational 23, Not applicable 12, Phase 4 4, Phase 3 9, Phase 2/3 5, Phase 2 12, Phase 1/2 5, Phase 1 5) 2008: 104 trials (Observational 23, Not applicable 20, Phase 4 8, Phase 3 9, Phase 2/3 3, Phase 2 20, Phase 1/2 11, Phase 1 10) 2009: 93 trials (Observational 22, Not applicable 22, Phase 4 6, Phase 3 11, Phase 2/3 3, Phase 2 18, Phase 1/2 6, Phase 1 5) 2010: 97 trials (Observational 24, Not applicable 29, Phase 4 3, Phase 3 6, Phase 2/3 5, Phase 2 13, Phase 1/2 4, Phase 1 13) 2011: 117 trials (Observational 17, Not applicable 33, Phase 4 8, Phase 3 15, Phase 2/3 5, Phase 2 12, Phase 1/2 10, Phase 1 17) 2012: 128 trials (Observational 26, Not applicable 43, Phase 4 8, Phase 3 11, Phase 2/3 5, Phase 2 16, Phase 1/2 5, Phase 1 14) 2013: 143 trials (Observational 27, Not applicable 56, Phase 4 11, Phase 3 9, Phase 2/3 4, Phase 2 22, Phase 1/2 4, Phase 1 10) 2014: 131 trials (Observational 25, Not applicable 54, Phase 4 3, Phase 3 11, Phase 2/3 3, Phase 2 12, Phase 1/2 10, Phase 1 13) 2015: 175 trials (Observational 45, Not applicable 71, Phase 4 7, Phase 3 11, Phase 2/3 2, Phase 2 18, Phase 1/2 8, Phase 1 13) 2016: 157 trials (Observational 34, Not applicable 63, Phase 4 5, Phase 3 7, Phase 2/3 2, Phase 2 22, Phase 1/2 13, Phase 1 11) 2017: 217 trials (Observational 52, Not applicable 98, Phase 4 6, Phase 3 14, Phase 2/3 4, Phase 2 20, Phase 1/2 5, Phase 1 18) 2018: 200 trials (Observational 38, Not applicable 101, Phase 4 11, Phase 3 12, Phase 2/3 2, Phase 2 19, Phase 1/2 8, Phase 1 9) 2019: 220 trials (Observational 49, Not applicable 95, Phase 4 7, Phase 3 11, Phase 2/3 3, Phase 2 35, Phase 1/2 6, Phase 1 14) 2020: 196 trials (Observational 51, Not applicable 79, Phase 4 4, Phase 3 8, Phase 2/3 12, Phase 2 24, Phase 1/2 4, Phase 1 14) 2021: 250 trials (Observational 60, Not applicable 119, Phase 4 6, Phase 3 15, Phase 2/3 3, Phase 2 26, Phase 1/2 7, Phase 1 14) 2022: 257 trials (Observational 53, Not applicable 139, Phase 4 5, Phase 3 12, Phase 2/3 5, Phase 2 11, Phase 1/2 10, Phase 1 22) 2023: 236 trials (Observational 62, Not applicable 124, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 12, Phase 1/2 9, Phase 1 14) 2024: 268 trials (Observational 58, Not applicable 139, Phase 4 8, Phase 3 2, Phase 2/3 2, Phase 2 21, Phase 1/2 12, Phase 1 26) 2025: 274 trials (Observational 63, Not applicable 130, Phase 4 7, Phase 3 7, Phase 2/3 7, Phase 2 21, Phase 1/2 11, Phase 1 28)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 287
2025 274
2024 268
2023 236
2022 257
2021 250
2020 196
2019 220
2018 200
2017 217

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 320 trials starting in 2026 and about 300 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 476 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 2,267 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Spinal Cord Diseases trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 317
Phase 1/2 185
Phase 2 434
Phase 2/3 95
Phase 3 262
Phase 4 140
Not applicable 1,638
Observational 891
Expanded access 20

How many Spinal Cord Diseases trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 202
Recruiting 632
Enrolling by invitation 48
Active, not recruiting 190
Available 4

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Spinal Cord Diseases trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 78
National Institute of Neurological Disorders and Stroke (NINDS) 53
GlaxoSmithKline 48
Swiss Paraplegic Research, Nottwil 45
US Department of Veterans Affairs 45

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Spinal Cord Diseases? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Riluzole 32
Nusinersen 25
Risdiplam 18
METHYLPREDNISOLONE 11

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
InfanrixTM hexa 18
MRI 18
Exercise 14
type A botulinum toxin 13
Transcranial Magnetic Stimulation 12

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Spinal Cord Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,078 128
Respiratory failure 593 71
Malignant neoplasm progression 430 4
Bronchiolitis 357 36
Dysphagia 281 54

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Spinal Cord Diseases? (246)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Gait function assessed using 3D gait analysis in patients with cervical spinal myelopathy before and after surgical decompression: a systematic review and meta-analysis. The spine journal : official journal of the North American Spine Society 2024 Yes
A minimum data set-Core outcome set, core data elements, and core measurement set-For degenerative cervical myelopathy research (AO Spine RECODE DCM): A consensus study. PLoS medicine 2024 Yes
Spinal cord lesion mimicking a dysimmune myelitis revealing CANVAS syndrome. The journal of spinal cord medicine 2023 Yes
Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis. Clinical neurology and neurosurgery 2023 Yes
Comparison of posterior muscle-preserving selective laminectomy and laminectomy with fusion for treating cervical spondylotic myelopathy: study protocol for a randomized controlled trial. Trials 2023 Yes

Showing 5 of 246 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages